#United States #Phoenix #Nanoscope Therapeutics #retinal therapy #MOGENRY

Nanoscope Therapeutics: Pioneering Advances in Eye Health

Nanoscope Therapeutics, Inc., a leading biotechnology company, is gearing up to make waves in the realm of gene therapy with its presentation at the prestigious Cell & Gene Meeting on the Mesa 2026. This key industry event, scheduled from October 5 to 7 in Phoenix, Arizona, will highlight innovations in cellular and gene therapies aimed at revitalizing healthcare systems.

Spotlight on Innovation

Samarendra Mohanty, co-founder, president, and chief scientific officer of Nanoscope Therapeutics, is set to deliver a highly anticipated Innovation Spotlight presentation during the conference. Attendees can expect insights into the company's pioneering work on MOGENRY® (sonpiretigene isteparvovec; MCO-010), a revolutionary optogenetic therapy tailored specifically for patients grappling with vision impairment due to inherited retinal disorders.

Scheduled for October 6 at 11:15 AM, Dr. Mohanty’s presentation will provide an update on the ongoing journey toward securing global approval for MOGENRY, which has already garnered significant attention from the FDA, currently under review through the Biologics License Application (BLA) process.

MOGENRY: A Game-Changer in Retinal Treatments

MOGENRY operates on Nanoscope’s unique MCO technology, which essentially involves a genetically engineered synthetic opsin designed to enhance light sensitivity in retinal cells. The elegance of this approach lies in its non-invasive nature: MOGENRY can be administered as a one-time injection in an office setting, eliminating the need for genetic testing or extensive surgical procedures.

Dr. Mohanty’s vision for this therapy reflects the decade-long research focused on improving patients' quality of life who suffer from degenerative retinal diseases. By making healthy retinal cells responsive to light, MOGENRY empowers patients to regain some degree of visual perception, thus transforming the standard of care for conditions like retinitis pigmentosa (RP).

A Rising Star in Biotechnology

Nanoscope Therapeutics is at the forefront of developing disease-agnostic therapies that target a spectrum of retinal diseases. The company's latest clinical trials, including the RESTORE Phase 2b/3 study, showcased promising results in treating RP, which prompted the FDA to accept the BLA for MOGENRY. With plans for additional trials in Stargardt disease (SD) and other genetic forms of retinal dystrophies, Nanoscope continues to push the envelope in optogenetic therapy.

The implications of these advancements are monumental: MOGENRY not only holds the potential to become a hallmark treatment within ophthalmology but also stands to benefit millions who are presently dealing with the debilitating effects of vision loss.

Emphasis on Collaboration

At the Mesa conference, Nanoscope welcomes the opportunity to engage with investors and potential collaborators. Leaders of the company will be available for discussions, prompting those interested in partnership opportunities to use the conference's partnering app or directly contact Nanoscope.

As the biotechnology sector navigates the complexities of therapeutic innovations, Nanoscope Therapeutics shines as a beacon of hope for those experiencing retinal degeneration. The upcoming presentation at the Mesa meeting is not just a corporate milestone, but a step towards reshaping the future for countless individuals in need of breakthrough solutions for visual impairment.

For further inquiries and meetings, interested parties are encouraged to reach out to Nanoscope directly as they prepare to unveil their latest developments in eye care at this significant industry event.